⏳ Fetching live dividend data...
Home › Calculator › SILO Dividend Calculator 2026
Silo Pharma, Inc. · NASDAQ
Price: $5.90 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in SILO → $185.2K in 10 years · $3,908.16/month
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SILO position with:
Real after-tax yield depends on where you live and how you hold SILO.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 33.90% | 31.10% | $3,390 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 28.81% | 26.01% | $2,881 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 27.12% | 24.32% | $2,712 / yr |
| 🇬🇧 UK ISA | 0% | 33.90% | 31.10% | $3,390 / yr |
| 🇬🇧 UK Taxable | 8.75% | 30.93% | 28.13% | $3,093 / yr |
| 🇨🇦 TFSA | 0% | 33.90% | 31.10% | $3,390 / yr |
| 🇨🇦 CA Taxable | 25% | 25.42% | 22.62% | $2,542 / yr |
| 🇦🇺 Super (pension) | 15% | 28.81% | 26.01% | $2,881 / yr |
| 🇦🇺 AU Taxable | 30% | 23.73% | 20.93% | $2,373 / yr |
| 🇩🇪 DE Taxable | 26.375% | 24.96% | 22.16% | $2,496 / yr |
| 🇫🇷 FR Taxable | 30% | 23.73% | 20.93% | $2,373 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
SILO pays quarterly — 4 times per year. Next ex-div: TBD.
How SILO compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SILO sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2025-12-15 | 2,500 | $0.42 | $1.1K | ||
| Buy | 2025-12-15 | 2,500 | $0.41 | $1.0K | ||
| Buy | 2025-11-21 | 1,000 | $0.36 | $365.00 | ||
| Buy | 2025-11-20 | 1,000 | $0.37 | $370.00 | ||
| Buy | 2025-11-19 | 4,500 | $0.41 | $1.8K | ||
| Buy | 2025-11-18 | 7,500 | $0.40 | $3.0K | ||
| Buy | 2025-05-27 | 10,000 | $0.43 | $4.3K | ||
| A-Award | 2025-05-23 | 50,000 | $0.43 | $21.4K | ||
| A-Award | 2025-05-23 | 50,000 | $0.43 | $21.4K | ||
| A-Award | 2025-05-23 | 50,000 | $0.43 | $21.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SILO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →